Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Arcadia Biosciences (RKDA) Announces Third-Quarter 2020 Financial Results and Business Highlights

      -- Executes strategic transaction with Bioceres Crop Solutions (BIOX), bringing $8 million in up-front and contingent cash, 1.875 million BIOX shares and trait royalties of up to $10 million on HB4® soybean sales

      -- Completes acquisition of Industrial Seed Innovations, expanding GoodHemp™ portfolio

      -- Launches multiple products on-line and in grocery stores with Three Farm Daughters to bring GoodWheat™ to consumers

      Arcadia Biosciences Logo (PRNewsfoto/Arcadia Biosciences, Inc.)

      News provided by

      Arcadia Biosciences, Inc.

      Nov 12, 2020, 08:00 ET

      Share this article

      Share this article


      DAVIS, Calif., Nov. 12, 2020 /PRNewswire/ -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today released its financial and business results for the third quarter of 2020.

      "I am pleased to report Arcadia has achieved a number of fundamental milestones, resulting in a stronger financial wherewithal to achieve our number one goal: driving near-term shareholder value by unlocking the full potential of our commercial-ready products," said Matthew Plavan, Arcadia's president and CEO. "Through a series of strategic transactions we're announcing today with our business partner Bioceres Crop Solutions (BIOX), commercialization of the HB4® soybean business and distribution of our GoodWheat portfolio of products into South and Central America is now in their capable hands, in exchange for cash, shares of BIOX and ongoing royalty payments to Arcadia for both HB4 soybean and GoodWheat sales."

      Continued Plavan, "Bioceres is the perfect commercial steward to advance the HB4 soybean into global markets, and we are delighted to share in the equity and revenue upside of the business while dedicating all of our time, attention and capital resources to the near-term scale-up of our GoodWheat and GoodHemp-branded products.  With the formal U.S. launch of Three Farm Daughters brand products powered by GoodWheat and the completion of our acquisition of Industrial Seed Innovations (ISI) and its popular hemp seed varieties, we have plenty of momentum to capitalize on." 

      Recent Operating and Business Highlights

      • Strategic Transactions with Bioceres Crop Solutions (BIOX).  Arcadia today is announcing a series of strategic transactions with BIOX, including the sale of its membership interest in Verdeca, a soybean joint venture the two companies formed in 2012. In another transaction, Bioceres acquired license rights to Arcadia's GoodWheat technologies in South and Central America, for which Arcadia will receive future royalties on all sales. Arcadia will also receive $6 million in cash, including reimbursement of transaction-related expenses and fees, with an additional $2 million in cash to be paid upon achievement by Verdeca of specific regulatory and commercial milestones. Arcadia also receives 1.875 million unregistered shares of BIOX common stock and trait royalties of up to $10 million on HB4 soybean sales.

      • Partnership with Three Farm Daughters to Develop and Market GoodWheat Products.  In the third quarter, Arcadia announced a strategic business venture with Three Farm Daughters, a majority female-owned North Dakota-based consumer food company, to develop and market food products using Arcadia's patented non-GMO GoodWheat technology. Since then, the companies have launched multiple Three Farm Daughters-branded food products, including pastas and flour, that leverage the enhanced nutritional profiles of GoodWheat ingredients. These products are now being sold regionally and through the company's e-commerce site: www.threefarmdaughters.com.

      • Acquisition of Innovative Hemp Seed Breeding Company.  Arcadia closed a transaction with Industrial Seed Innovations (ISI), an Oregon-based industrial hemp breeding and seed company, to acquire its commercial and genetic assets, including seed varieties, germplasm library and intellectual property. ISI's popular Rogue and Umpqua seed varieties will become part of Arcadia's portfolio, alongside the company's GoodHemp line of genetically superior hemp seeds, transplants and extracts. The acquisition significantly broadens and accelerates commercialization of Arcadia's hemp-related breeding platform and establishes a breeding research and development facility in the Pacific Northwest, a key hemp production area.

      • Collaboration with Corner Foods to Bring GoodWheat to China and Israel. Arcadia's collaboration with Corner Foods, an affiliate of Corner Capital Group, brings Arcadia's GoodWheat portfolio of non-GMO specialty wheat ingredients to China and expanding in the future to Israel. The partnership will introduce GoodWheat products directly to consumers in China via popular e-commerce site TMall and cooking and lifestyle network Tastemade China. Together, these digital platforms reach an estimated 8 million consumers in China per month.

      • Collaboration with GoodMills to Sell GoodWheat in Europe. Through a collaboration with GoodMills Innovation, an affiliate of GoodMills Group, Europe's largest milling company, Arcadia plans to commercialize GoodWheat varieties across Europe, introducing uniquely healthy products for the retail, consumer and food service sectors beginning in 2021. GoodMills Innovation is recognized as one of the world's leading innovators in grain-based ingredients that are both highly functional and nutritional.

      • Global Scale-up Underway for HB4 Drought Resistant, Herbicide Tolerant Soybeans. Through its Verdeca joint venture with Bioceres Crop Solutions, Arcadia successfully harvested foundation seed to enable up to 90,000 hectares in preparation for regulatory approval from China. Verdeca is also increasing breeding and new market development activities to access incremental geographies, including Brazil and the U.S.

      • Expansion of Intellectual Property Protection for GoodWheat Portfolio. Arcadia strengthened its intellectual property and GoodWheat technology portfolio with five additional U.S. patents in Q2. The U.S. Patent and Trademark Office awarded the company two patents for extending the shelf life of whole wheat by minimizing hydrolytic and oxidative rancidity. The company also received notices of allowance for three additional patents extending earlier claims surrounding the extended shelf life of wheat and reduced gluten grains. The new patents bring the total number of patents in Arcadia's GoodWheat portfolio of non-GMO wheat varieties to 23.

      • Foundational Patents for Non-GMO Herbicide Tolerant Wheat. The Australian Patent Office granted patents to Arcadia covering herbicide tolerance in wheat, and the U.S. Patent and Trademark Office issued a notice of allowance for the same technology, with patents pending in other territories. Arcadia's herbicide tolerant wheat technology can be an important tool in the hybrid breeding toolkit. This technology will serve as the foundation for future innovation and could open the door to development of a highly efficient hybrid wheat production system, which would transform the 200 million hectare global wheat industry.

      • Warrant Exercise Transaction Generated $2.6M in Gross Proceeds. Arcadia strengthened its balance sheet through a warrant exercise transaction in the third quarter, providing additional cash resources to persevere through the headwinds of the COVID-19 pandemic.

      Arcadia Biosciences, Inc.

      Financial Snapshot

      (Unaudited)

      ($ in thousands)



      Three Months Ended September 30,


      Nine Months Ended September 30,


      2020

      2019

      Favorable/

      (Unfavorable)


      2020

      2019

      Favorable/

      (Unfavorable)




      $

      %




      $

      %

      Total revenues

      314

      392

      (78)

      (20%)


      904

      753

      151

      20%

      Total operating expenses

      7,895

      6,585

      (1,310)

      (20%)


      21,151

      16,145

      (5,006)

      (31%)

      Loss from operations

      (7,581)

      (6,193)

      (1,388)

      (22%)


      (20,247)

      (15,392)

      (4,855)

      (32%)

      Net loss attributable to common stockholders

      (6,391)

      (14,187)

      7,796

      55%


      (13,553)

      (22,562)

      9,009

      40%

      Revenues
      In the third quarter of 2020, revenues were $314,000, compared to revenues of $392,000 in the third quarter of 2019 and for the nine months ended September 30, 2020, revenues were $904,000, compared to $753,000 during the same period in 2019. The quarter-over-quarter revenue decrease was driven by a decrease in contract research and government grants revenue, partially offset by an increase in GLA product sales and GoodWheat royalty revenues. The nine months period increase was driven primarily by a milestone achievement by a licensee in the first quarter of 2020, as well as the increase in GLA product sales and GoodWheat royalty revenues.

      Operating Expenses
      In the third quarter of 2020, operating expenses were $7.9 million, compared to $6.6 million in the third quarter of 2019 and for the nine months ended September 30, 2020, operating expenses were $21.2 million, compared to $16.1 million during the same period in 2019.

      Research and development (R&D) costs decreased by $169,000 and increased by $612,000 for the third quarter and nine months ended September 30, 2020, respectively. The third quarter decrease was the result of lower soy related costs somewhat offset by higher hemp-related research costs. The increase for the nine months ended September 30, 2020 was primarily driven by higher employee expenses and hemp-related research costs.

      General and administrative (SG&A) costs decreased by $185,000 and increased by $1.3 million for the third quarter and nine months ended September 30, 2020, respectively. The third quarter decrease was mainly comprised of lower employee expenses partially offset by higher consulting fees. The increase for the nine months ended September 30, 2020 was primarily the result of higher consulting fees, consultants' stock compensation expenses and insurance premiums.

      Cost of product revenues increased by $1.7 million and $3.1 million for the third quarter and nine months ended September 30, 2020, respectively. The third quarter increase was due to a $1.3 million inventory write-off for Arcadia's Archipelago joint venture in response to a recently issued regulatory ruling. The increase for the nine months ended September 30, 2020 was comprised of the third quarter inventory write-off, in addition to the $1.6 million write-down of GoodHemp inventory that did not meet Arcadia's required minimum quality specifications during the first half of 2020.

      Net Loss Attributable to Common Stockholders
      Net loss attributable to common shareholders for the third quarter of 2020 was $6.4 million, or ($0.60) per share, a $7.8 million decrease from the $14.2 million, or $2.04 per share, net loss recognized in the third quarter of 2019. The quarter-over-quarter decrease was largely due to the $7.8 million non-cash expense recognized in the third quarter of 2019 as a result of a significant increase in the fair value of common stock warrant liabilities compared to $1.1 million of non-cash income recognized in the third quarter of 2020 associated with a decrease in these liabilities.

      Net loss attributable to common shareholders for the nine months ended September 30, 2020 was $13.6 million, or ($1.42) per share, a $9.0 million decrease from the $22.6 million, or ($4.03) per share, net loss recognized for the nine months ended September 30, 2019.

      Conference Call and Webcast
      The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) today, November 12, to discuss third-quarter financial results, company operations and key strategic achievements.

      Interested participants can join the conference call using the following numbers:

      U.S. Toll-Free Dial-In: 

      +1-844-243-4690

      International Dial-In: 

      +1-225-283-0138

      Passcode:

      1303009

      A live webcast of the conference call will be available on the "Investors" section of Arcadia's website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company's investor website.

      About Arcadia Biosciences, Inc.
      Arcadia Biosciences (Nasdaq: RKDA) is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company's GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company's GoodHemp™ seed catalog delivers genetically superior hemp seeds and clones, applying the company's proprietary crop innovation technology, ArcaTech™, to an emerging crop. Arcadia's agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. For more information, visit www.arcadiabio.com.

      Safe Harbor Statement
      "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to the collaboration with Corner Foods, the partnership with Three Farm Daughters, the collaboration with GoodMills Innovation, revenue in 2020, financial performance in 2021, the acquisition of assets from Industrial Seed Innovations and the growth of the company. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the price and demand for the company's wheat and hemp related products are lower than expected; the company's and its partners' and affiliates' ability to develop and sell commercial products incorporating its traits, and complete the regulatory review process for such products; the company's and it partners' ability to fulfill current and follow-on purchase commitments; the company's compliance with laws and regulations that impact the company's business, and changes to such laws and regulations; the growth of the global wheat and hemp markets; the successful integration of the company's business with the businesses of any future partners; the potential impact of COVID-19 on the company's business; the successful closing of the acquisition of Industrial Seed Innovations; and the company's future capital requirements and ability to satisfy its capital needs.  Further information regarding these and other factors that could affect the company's financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled "Risk Factors" and additional information set forth in its Form 10-K for the year ended December 31, 2019, and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update these forward-looking statements.

      LinkedIn: Arcadia Biosciences 
      Twitter: @ArcadiaAg

      Arcadia Biosciences, Inc.

      Condensed Consolidated Balance Sheets

      (Unaudited)

      (In thousands, except share data)



      September 30,
      2020



      December 31,
      2019


      Assets








      Current assets:








      Cash and cash equivalents

      $

      10,201



      $

      8,417


      Short-term investments


      —




      16,915


      Accounts receivable


      373




      602


      Inventories, net — current


      9,416




      1,794


      Prepaid expenses and other current assets


      1,204




      712


      Total current assets


      21,194




      28,440


      Restricted cash


      2,001




      —


      Property and equipment, net


      3,484




      1,799


      Right of use asset


      6,013




      1,963


      Inventories, net — noncurrent


      461




      364


      Goodwill


      301




      -


      Intangible assets, net


      400




      -


      Other noncurrent assets


      23




      8


      Total assets

      $

      33,877



      $

      32,574


      Liabilities and stockholders' equity








      Current liabilities:








      Accounts payable and accrued expenses

      $

      6,711



      $

      4,685


      Amounts due to related parties


      29




      40


      Debt — current


      705




      24


      Unearned revenue — current


      —




      42


      Operating lease liability — current


      700




      611


      Other current liabilities


      263




      306


      Total current liabilities


      8,408




      5,708


      Debt — noncurrent


      2,548




      107


      Operating lease liability — noncurrent


      5,574




      1,497


      Common stock warrant liabilities


      3,065




      14,936


      Other noncurrent liabilities


      2,280




      2,000


      Total liabilities


      21,875




      24,248


      Commitments and contingencies (Note 14)








      Stockholders' equity:








      Common stock, $0.001 par value—
        150,000,000 shares authorized as
      of September 30, 2020
        and December 31, 2019; 10,832,203
      and 8,646,149
        shares issued and outstanding as of September 30,
      2020
        and December 31, 2019, respectively


      51




      49


      Additional paid-in capital


      231,954




      214,826


      Accumulated other comprehensive income


      —




      1


      Accumulated deficit


      (220,725)




      (207,171)


      Total Arcadia Biosciences stockholders' equity


      11,280




      7,705


      Non-controlling interest


      722




      621


      Total stockholders' equity


      12,002




      8,326


      Total liabilities and stockholders' equity

      $

      33,877



      $

      32,574


      Arcadia Biosciences, Inc.

      Condensed Consolidated Statements of Operations and Comprehensive Loss

      (Unaudited)

      (In thousands, except share and per share data)



      Three Months Ended
      September 30,


      Nine Months Ended
      September 30,




      2020




      2019



      2020




      2019


      Revenues:















      Product

      $

      245



      $

      216


      $

      630



      $

      485


      License


      10




      17



      110




      17


      Royalty


      16




      —



      58




      —


      Contract research and government grants


      43




      159



      106




      251


      Total revenues


      314




      392



      904




      753


      Operating expenses:















      Cost of product revenues


      1,841




      177



      3,463




      324


      Research and development


      1,762




      1,931



      5,999




      5,387


      Selling, general and administrative


      4,292




      4,477



      11,689




      10,434


      Total operating expenses


      7,895




      6,585



      21,151




      16,145


      Loss from operations


      (7,581)




      (6,193)



      (20,247)




      (15,392)


      Interest expense


      (23)




      (3)



      (32)




      (3)


      Other income, net


      -




      119



      83




      339


      Change in fair value of common stock warrant liabilities


      1,130




      (7,777)



      6,212




      (6,790)


      Loss on extinguishment of warrant liability


      (682)




      —



      (635)




      —


      Offering costs


      —




      (336)



      -




      (702)


      Net loss before income taxes


      (7,156)




      (14,190)



      (14,619)




      (22,548)


      Income tax benefit (provision)


      (9)




      3



      (15)




      (14)


      Net loss


      (7,165)




      (14,187)



      (14,634)




      (22,562)


      Net loss attributable to non-controlling interest


      (774)




      —



      (1,081)




      —


      Net loss attributable to common stockholders

      $

      (6,391)



      $

      (14,187)


      $

      (13,553)



      $

      (22,562)


      Net loss per share attributable to common stockholders:















      Basic and diluted

      $

      (0.60)



      $

      (2.04)


      $

      (1.42)



      $

      (4.03)


      Weighted-average number of shares used in per share

         calculations:















      Basic and diluted


      10,719,618




      6,942,612



      9,570,259




      5,596,545


      Other comprehensive loss, net of tax















      Unrealized losses on available-for-sale securities


      —




      (1)



      (1)




      —


      Other comprehensive loss


      —




      (1)



      (1)




      —


      Comprehensive loss attributable to common stockholders

      $

      (6,391)



      $

      (14,188)


      $

      (13,554)



      $

      (22,562)


      Arcadia Biosciences, Inc.

      Condensed Consolidated Statements of Cash Flows

      (Unaudited)

      (In thousands)



      Nine Months Ended September 30,



      2020




      2019

      CASH FLOWS FROM OPERATING ACTIVITIES:







      Net loss

      $

      (14,634)



      $

      (22,562)

      Adjustments to reconcile net loss to cash used in operating activities:







      Change in fair value of common stock warrant liabilities


      (6,212)




      6,790

      Loss on extinguishment of warrant liability


      635




      —

      Offering costs


      -




      702

      Depreciation


      395




      133

      Lease amortization


      745




      530

      (Gain) Loss on disposal of equipment


      (8)




      1

      Net amortization of investment premium


      (44)




      (121)

      Stock-based compensation


      1,844




      1,870

      Write-down of inventory and prepaid production costs


      3,063




      —

      Changes in operating assets and liabilities:







      Accounts receivable


      229




      38

      Unbilled revenue


      -




      3

      Inventories


      (9,609)




      (1,411)

      Prepaid expenses and other current assets


      (1,157)




      (36)

      Other noncurrent assets


      (15)




      —

      Accounts payable and accrued expenses


      2,026




      2,425

      Amounts due to related parties


      (11)




      (1)

      Other current liabilities


      (43)




      3

      Unearned revenue


      (42)




      (16)

      Operating lease payments


      (629)




      (534)

      Net cash used in operating activities


      (23,467)




      (12,186)

      CASH FLOWS FROM INVESTING ACTIVITIES:







      Proceeds from sale of property and equipment


      8




      1

      Purchases of property and equipment


      (2,038)




      (878)

      Acquisitions, net of cash acquired


      (500)




      —

      Purchases of investments


      (1,292)




      (18,458)

      Proceeds from sales and maturities of investments


      18,250




      18,050

      Net cash provided by (used in) investing activities


      14,428




      (1,285)

      CASH FLOWS FROM FINANCING ACTIVITIES:







      Proceeds from issuance of common stock and warrants from June 2019 Offering


      9,372




      7,500

      Proceeds from borrowings


      3,108




      —

      Payments of transaction costs relating to extinguishment of warrant liability


      (863)




      —

      Proceeds from issuance of common stock and warrants from Purchase Agreement


      —




      10,000

      Payments of offering costs relating to September 2019 Offering


      —




      (776)

      Payments of offering costs relating to June 2019 Offering


      —




      (663)

      Payments of offering costs relating to June 2018 Offering


      —




      (24)

      Principal payments on notes payable


      (26)




      (2)

      Proceeds from the exercise of warrants


      —




      5,269

      Proceeds from ESPP purchases


      51




      21

      Capital contributions received from non-controlling interest


      1,182




      689

      Net cash provided by financing activities


      12,824




      22,014

      Net increase in cash, cash equivalents and restricted cash


      3,785




      8,543


      Cash, cash equivalents and restricted cash — beginning of period


      8,417




      11,998


      Cash, cash equivalents and restricted cash — end of period

      $

      12,202



      $

      20,541


      SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:








      Cash paid for income taxes

      $

      1



      $

      2


      Cash paid for interest

      $

      7



      $

      —


      NONCASH INVESTING AND FINANCING ACTIVITIES:








      Fixed assets acquired with notes payable

      $

      37



      $

      139


      Common stock warrants issued to placement agent and included in offering costs related to May 2020 Warrant Transaction

      $

      215



      $

      —


      Common stock warrants issued to placement agent and included in offering costs related to July 2020 Warrant Transaction

      $

      101



      $

      —


      Offering costs in accounts payable and accrued expenses at end of period

      $

      —



      $

      21


      Common stock warrants issued to placement agent and included in offering costs related to June 2019 Offering

      $

      —



      $

      86


      Common stock warrants issued to placement agent and included in offering costs related to September 2019 Offering

      $

      —



      $

      95


      Reclassification of common stock warrant liability balance with warrant exercises





      $

      7,016


      Right of use assets obtained in exchange for new operating lease liabilities

      $

      4,157



      $

      2,328


      Purchases of fixed assets included in accounts payable and accrued expenses

      $

      —



      $

      6


      SOURCE Arcadia Biosciences, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.